Outcomes of multisite antimicrobial stewardship programme implementation with a shared clinical decision support system by Bond, Stuart et al.
University of Wollongong
Research Online
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health
2017
Outcomes of multisite antimicrobial stewardship
programme implementation with a shared clinical
decision support system
Stuart Bond
University of Wollongong, Wollongong Hospital, seb708@uowmail.edu.au
Adriana J. Chubaty
Prince Of Wales Hospital, Randwick
Suman Adhikari
St George Hospital, University of New South Wales
Spiros Miyakis
University of Wollongong, Wollongong Hospital, smiyakis@uow.edu.au
Craig S. Boutlis
Wollongong Hospital, cboutlis@uow.edu.au
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Bond, S. E., Chubaty, A. J., Adhikari, S., Miyakis, S., Boutlis, C. S., Yeo, W. W., Batterham, M. J., Dickson, C., McMullan, B. J.,
Mostaghim, M. et al (2017). Outcomes of multisite antimicrobial stewardship programme implementation with a shared clinical
decision support system. Journal of Antimicrobial Chemotherapy, 72 (7), 2110-2118.
Outcomes of multisite antimicrobial stewardship programme
implementation with a shared clinical decision support system
Abstract
Background: Studies evaluating antimicrobial stewardship programmes (ASPs) supported by computerized
clinical decision support systems (CDSSs) have predominantly been conducted in single site metropolitan
hospitals.
Objectives: To examine outcomes of multisite ASP implementation supported by a centrally deployed
CDSS.
Methods: An interrupted time series study was conducted across five hospitals in New South Wales,
Australia, from 2010 to 2014. Outcomes analysed were: effect of the intervention on targeted antimicrobial
use, antimicrobial costs and healthcare-associated Clostridium difficile infection (HCA-CDI) rates. Infection-
related length of stay (LOS) and standardized mortality ratios (SMRs) were also assessed.
Results: Post-intervention, antimicrobials targeted for increased use rose from 223 to 293 defined daily doses
(DDDs)/1000 occupied bed days (OBDs)/month (+32%, P < 0.01). Conversely, antimicrobials targeted for
decreased use fell from 254 to 196 DDDs/1000 OBDs/month (−23%; P < 0.01). These effects diminished
over time. Antimicrobial costs decreased initially (−AUD$64551/month; P < 0.01), then increased
(+AUD$7273/month; P < 0.01). HCA-CDI rates decreased post-intervention (−0.2 cases/10 000 OBDs/
month; P < 0.01). Proportional LOS reductions for key infections (respiratory from 4.8 to 4.3 days, P < 0.01;
septicaemia 6.8 to 6.1 days, P < 0.01) were similar to background LOS reductions (2.1 to 1.9 days). Similarly,
infection-related SMRs (observed/expected deaths) decreased (respiratory from 1.1 to 0.75; septicaemia 1.25
to 0.8; background rate 1.19 to 0.90.
Conclusions: Implementation of a collaborative multisite ASP supported by a centrally deployed CDSS was
associated with changes in targeted antimicrobial use, decreased antimicrobial costs, decreased HCA-CDI
rates, and no observable increase in LOS or mortality. Ongoing targeted interventions are suggested to
promote sustainability.
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Studies evaluating antimicrobial stewardship programs (ASPs) supported by computerised 46 
clinical decision support systems (CDSSs) have predominantly been conducted in single site 47 
metropolitan hospitals. The aim of this study was to examine outcomes of multisite ASP 48 
implementation supported by a centrally deployed CDSS. 49 
Methods 50 
An interrupted time series study of a CDSS-supported multisite ASP was conducted across 51 
five hospitals in New South Wales, Australia from 2010 to 2014. Outcomes analysed were: 52 
effect of the intervention on targeted antimicrobial use, antimicrobial costs, healthcare 53 
associated Clostridium difficile infection (HCA-CDI) rates, infection-related length of stay 54 
(LOS), and standardised mortality ratios (SMRs). 55 
Results 56 
Post-intervention, antimicrobials targeted for increased use rose from 223 to 293 defined 57 
daily doses (DDDs)/1000 occupied bed days (OBDs)/month (+32%, p<0.01). Conversely, 58 
antimicrobials targeted for decreased use fell from 254 to 196 DDDs/1000 OBDs/month (-59 
23%; p<0.01). These effects diminished over time. Antimicrobial costs decreased initially (-60 
AUD$64,551/month; p<0.01), then increased (+AUD$7,273/month; p<0.01). HCA-CDI rates 61 
decreased post-intervention (-0.2 cases/10,000 OBDs/month; p<0.01). Proportional LOS 62 
reductions for key infections (respiratory 4.8 to 4.3 days, p<0.01; septicaemia 6.8 to 6.1 63 
days, p<0.01) were similar to background LOS reductions (2.1 to 1.9 days). Similarly, 64 
 
 
infection-related SMRs (observed/expected deaths) decreased (respiratory 1.1 to 0.75, 65 
p<0.01; septicaemia 1.25 to 0.8, p<0.01; background rate 1.19 to 0.90, p<0.01).  66 
Conclusions 67 
Implementation of collaborative multisite ASP supported by a centrally deployed CDSS was 68 
associated with changes in targeted antimicrobial use, decreased antimicrobial costs, 69 
decreased HCA-CDI rates, and no observable increase in LOS or mortality. Ongoing targeted 70 
interventions are suggested to promote sustainability. 71 




Antimicrobial stewardship programs (ASPs) aim to improve appropriateness of antimicrobial 74 
prescribing with the goals of more effectively treating and preventing infections, while 75 
curbing antimicrobial resistance and reducing adverse effects.1, 2 Studies examining the 76 
impact of ASPs have primarily been conducted in tertiary metropolitan hospitals.3-8 There is 77 
limited literature describing clinical outcomes from collaboratively implemented ASPs across 78 
multiple hospital sites.8-11 Previous single site ASP studies have demonstrated benefits using 79 
a computerised clinical decision support system (CDSS), antimicrobial restriction, and 80 
prospective audit and feedback.3-6, 12 These benefits include a reduction in targeted 81 
antimicrobial use,4, 12, 13 antimicrobial drug acquisition costs,4, 13, 14 and healthcare associated 82 
Clostridium difficile infection (HCA-CDI) rates.13, 15 An evidence gap exists for 83 
implementation of ASPs across multiple sites using a centrally deployed CDSS.2  84 
Metrics for evaluating ASPs include antimicrobial use, drug costs, adverse effects such as 85 
HCA-CDI and antimicrobial resistance, length of stay (LOS), and mortality.16, 17 Infection-86 
related outcomes related to community-acquired pneumonia (CAP), skin and soft tissue 87 
infections and septicaemia have been also been recommended.16 Although there are 88 
confounders associated with their use as ASP metrics,  LOS and mortality are useful 89 
balancing measures to address potential unintended consequences.12  90 
To our knowledge, no studies of multisite ASPs using a centrally deployed CDSS have 91 
included non-metropolitan hospitals. The aims of this study were to evaluate the impact of a 92 
CDSS-supported, multisite ASP on antimicrobial use, antimicrobial costs, HCA-CDI rates, 93 





In 2012 a multisite ASP supported by a centrally deployed CDSS was implemented in 12 97 
hospital sites (Figure 1) across the South Eastern Sydney and Illawarra Shoalhaven Local 98 
Health Districts, and Sydney Children’s Hospital, all in New South Wales (NSW), Australia. 99 
These districts cover a geographic area of 6,331 square kilometres and have an estimated 100 
population of 1.17 million, extending from central Sydney to three hours’ drive south.18 101 
Comparable adult metrics were available for analysis in five hospitals, comprising 1900 beds, 102 
as shown in Figure 1. The remaining hospitals were not included in the study for the 103 
following reasons: small size, ASP implementation outside of study period, specialist (i.e. 104 
obstetrics, paediatrics) or subacute admissions (Figure 1). Those attributes would not allow 105 
comparison of outcomes such as antimicrobial use, LOS or HCA-CDI. The specialist paediatric 106 
hospital contributed to the development of guidelines for paediatric services within the 107 
other hospitals. Hospitals shared antimicrobial stewardship strategies, including a centrally 108 
deployed CDSS (Guidance MS®, Melbourne Health19), educational material and similar 109 
antimicrobial formulary restrictions. Further information on case complexity and case mix of 110 
the included study hospitals is provided in Supplementary Table 1. 111 
Intervention 112 
An interrupted time series (ITS) study was conducted combining data from five acute 113 
hospitals. The intervention point for the ASP was defined as the go-live date of the CDSS 114 
with concurrent dissemination of standardised clinical guidelines at each site (May-July 115 
2012). This occurred in the setting of a 6-month lead-in period of prior education and clinical 116 
 
 
guideline development (Figure 1). The fully modifiable CDSS, Guidance MS® is an intranet 117 
browser-based CDSS that guides prescribers on appropriate use and generates approvals for 118 
antimicrobials.19 Antimicrobial restriction (a key component of our ASP) within the CDSS is 119 
determined on the basis of spectrum of action, potential toxicity or cost.19 Implementation 120 
of the CDSS used project methodology (PRINCE2®, ILX Group, Mulgrave, Victoria, Australia) 121 
and was overseen by a multidisciplinary committee of medical, pharmacy, information 122 
technology (IT), and executive staff.  The committee met monthly via teleconference and 123 
collaborated closely throughout the project implementation period (May 2011 - May 2012). 124 
This period was critical to optimise organisational readiness for implementation of a CDSS-125 
supported ASP.1  126 
Clinical guidelines were standardised across the hospitals and incorporated into the CDSS. 127 
The development of guidelines, educational content and decision support was shared by 128 
adult and paediatric Infectious Diseases (ID) physicians and antimicrobial stewardship 129 
pharmacists. This allowed for a standardised intervention that was tailored to hospital size 130 
and level of acuity (Figure 1), thereby reducing individual hospital workload, allowing access 131 
to clinical expertise at smaller sites and ensuring timely consensus on CDSS clinical content. 132 
Staffing (ID physicians, pharmacists and microbiologists) varied across the hospital sites, so 133 
intranet-based guidelines and an antibiotic advice hotline were used to promote access to 134 
program resources. Standardised bimonthly nationally benchmarked antimicrobial usage 135 
audits were reported to respective hospital antimicrobial stewardship committees.20 Prior 136 
to the study, antimicrobial stewardship activities were restricted to phone-based advice, 137 
formal infectious diseases consults, some selective microbiology reporting and a phone-138 
based approval system at one study hospital (Figure 1). Study investigators classified the 139 
 
 
most commonly used antimicrobial classes into two categories, either targeted for increased 140 
or decreased use. Categorisation was based on the following factors: local antimicrobial 141 
resistance patterns, local use compared with benchmarked hospitals,20 risk of HCA-CDI and 142 
other side effects, compliance with antibiotic guidelines,21 and cost. Antimicrobials targeted 143 
for increased use were benzylpenicillin, doxycycline and aminopenicillins, whereas 144 
antimicrobials targeted for decreased use were third generation cephalosporins, macrolides, 145 
anti-pseudomonal beta-lactam/beta-lactamase inhibitor combinations, fluoroquinolones, 146 
and carbapenems. Some antimicrobials were targeted for increased use in some settings, 147 
but decreased use in others. For example, local quality audits identified underdosing in 148 
surgical prophylaxis, but unnecessarily long duration of therapy in other settings such as 149 
cellulitis (data not shown). Such antimicrobials (i.e. first generation cephalosporins, 150 
flucloxacillin, aminoglycosides, and vancomycin) were only included in the overall 151 
antimicrobial use analysis.  152 
There were no major changes to infection control policies related to either Clostridium 153 
difficile or hand hygiene during the study period. Infection control measures recommended 154 
by local policies included: isolation in single rooms; use of disposable gowns and gloves; 155 
hand hygiene with alcohol-based hand rub and/or soap and water; and terminal cleaning 156 
with chlorine-based disinfectant. Diagnostic testing methods were standardised from May 157 
2010, and comprised first line testing with targeted glutamate dehydrogenase (GDH) 158 
antigen and toxins A and B (C. Diff Quik Chek Complete®, Techlab, Blacksburg, VA, USA). 159 
Discordant results occasioned the use of a polymerase chain reaction (PCR; GeneXpert®, 160 
Cepheid, Sunnyvale, CA, USA) test. All diarrhoeal stools were subjected to testing from 161 




The effect of the intervention was assessed by: (1) change in antimicrobials targeted for 164 
increased use (benzylpenicillin, doxycycline and aminopenicillins) expressed as defined daily 165 
doses (DDDs) per 1000 occupied bed days (OBDs); (2) change in antimicrobials targeted for 166 
decreased use (third generation cephalosporins, macrolides, anti-pseudomonal beta-167 
lactam/beta-lactamase inhibitor combinations, fluoroquinolones, and carbapenems; 168 
DDDs/1000 OBDs);22 (3) change in total monthly antimicrobial costs (Australian dollars 169 
[AUD$]). High cost antifungals (liposomal amphotericin, anidulafungin, caspofungin, 170 
posaconazole, and voriconazole) were analysed separately to the main antimicrobial group, 171 
due to small variations in use accounting for large cost variations; (4) change in HCA-CDI 172 
rates, defined as a positive laboratory test for toxigenic Clostridium difficile plus diarrhoea 173 
onset greater than 48 hours after hospital admission (HCA-CDI cases per 10,000 OBDs);23 174 
and (5) change in LOS and in-hospital SMR for respiratory tract infections, cellulitis, kidney 175 
and urinary tract infections, and septicaemia, compared with background figures for all 176 
conditions (infectious and non-infectious combined). Confounders for each of the above 177 
measures were also investigated and reported where appropriate. Those included infection 178 
outbreaks, updated guidelines, changes to drug acquisition costs and administrative 179 
changes. 180 
Data sources 181 
Adult inpatient data were included from May 2010 to July 2014. Antimicrobial use and 182 
acquisition cost data were obtained from pharmacy dispensing software, iPharmacy® 183 
Versions 5.5 and 5.6 (CSC, Sydney, Australia). Antimicrobial use data were processed by the 184 
National Antimicrobial Utilisation Surveillance Program (NAUSP)20 using WHO classifications. 185 
 
 
Occupied bed day data were sourced from the hospitals’ performance units. HCA-CDI 186 
numbers were provided by the infection control teams in line with standardised surveillance 187 
and reporting.23 LOS (using Australian refined diagnosis related groups24) and SMRs (using 188 
principal diagnosis codes, based on International Classification of Diseases, 10th revision, 189 
Australian modification24) were provided by the performance units for the following key 190 
infections: respiratory infections/inflammations (predominantly pneumonia), cellulitis, and 191 
kidney and urinary tract infections. Those were the commonest treatment indications for 192 
antimicrobials in the 2014 Australian National Antimicrobial Prescribing Survey (NAPS).25 193 
Septicaemia was also included due to its high mortality.26 LOS and SMRs were compared for 194 
the time periods 1 July 2010 – 30 June 2012 and 1 July 2012 – 30 June 2014, as only data 195 
aligned with Australian financial years was available. Analysis of overall LOS excluded day 196 
case haemodialysis admissions. Comparative case complexity and case mix of the study 197 
hospitals was reported using National Weighted Activity Units (NWAUs)27 and diagnosis 198 
related groups (Supplementary Table 1).24 199 
Statistical analyses 200 
Interrupted time series (ITS) analysis with segmented linear regression was used to examine 201 
the impact of the intervention on monthly antimicrobial use, costs and HCA-CDI, estimating 202 
the immediate effects of the intervention and changes in trend.28 To account for seasonal 203 
variations, 24 time points one month apart were used pre- and post-intervention.14 To allow 204 
for statistical analysis of two years pre- and two years post-intervention, the intervention 205 
point (go-live date of CDSS) was aligned for the five hospitals, with individual hospital data 206 
included as Supplementary Tables 2-11. Definitions for ITS were: (1) initial level, model-207 
predicted level (antimicrobial use, cost, HCA-CDI) 24 months pre-intervention; (2) initial 208 
 
 
trend,  model-predicted monthly trend pre-intervention; (3) change in level (immediate 209 
effect), model-predicted difference between the level at the end of the pre-intervention 210 
period and commencement of the post-intervention period;3 (4) change in trend, model-211 
predicted difference between monthly initial (pre-intervention) trend and post-intervention 212 
trend. Autocorrelation using Newey-West approximation for standard errors was 213 
investigated and an appropriate lag was used when necessary, in order to assess for 214 
similarity between observations.28 LOS was assessed using Mann-Whitney U-test. A logistic 215 
regression model was used to calculate the number of expected deaths using: age; sex; 216 
admission type (emergency or acute); admission source (acute transfer or other); principal 217 
diagnosis, and Charlson Comorbidity Index (0, 1-2, or 3+).29 Additional variables used in the 218 
expected deaths analysis related to vascular surgery, cardiac surgery, neurosurgery, trauma 219 
and transplant. Those figures were then used to calculate infection-related and total SMR 220 
(actual deaths/expected deaths). SMRs (pre- and post-intervention) were expressed with 221 
95% CIs. Statistical significance was considered p<0.05. Statistical analyses were performed 222 
using Stata® Statistical Software: Release 14 (Statacorp 2015; College Station, TX, USA). 223 
Ethics approval was obtained from the districts’ Human Research Ethics Committees, 224 




Antimicrobial use 227 
Following the intervention, a rise in antimicrobials targeted for increased use of 70 228 
DDDs/1000 OBDs (+32%; p<0.01) was observed, followed by a decline in trend of 3.5 229 
DDDs/1000 OBDs per month (p<0.01). A concomitant reduction in antimicrobials targeted 230 
for decreased use of 58 DDDs/1000 OBDs (-23%; p<0.01) was observed, followed by a rise in 231 
trend of 3.4 DDDs/1000 OBDs per month (p<0.01; Table 1, Figure 2). No significant change 232 
in level or trend was observed for overall antimicrobial use. There was a national shortage 233 
of benzylpenicillin in 2010-11; ampicillin was recommended as an alternative for most 234 
benzylpenicillin indications during this time. The national antimicrobial guidelines21, 30 were 235 
updated in 2010 and again in 2014. 236 
Antimicrobial costs 237 
There was a significant reduction in total monthly antimicrobial costs of AUD$64,551 (-17%; 238 
p<0.01) post-intervention, followed by an increase in trend of AUD$7,273 per month 239 
(p<0.01; Table 2). This corresponded to a reduction of AUD$1.70/OBD post-intervention (-240 
20%; p<0.01), with a subsequent increase in trend of AUD$0.26/OBD per month (p<0.01). 241 
High cost antifungals demonstrated an immediate cost reduction (p<0.01), with no 242 
significant increase in trend. Some changes in acquisition costs were noted prior to the 243 
intervention, most notably a reduction in meropenem acquisition costs in mid-2011.  244 
HCA-CDI rates 245 
HCA-CDI rates were increasing pre-intervention from 2.8 to 6.2 cases/10,000 OBDs per 246 
month (p<0.01). A reduction was demonstrated post-intervention (-1.2 cases/10,000 247 
 
 
OBDs/month, p=0.15), followed by a decrease in trend (p<0.01; Table 2, Figure 3). There 248 
were no systemic changes to hand hygiene, isolation or cleaning policies during the study 249 
period. The rate of hand hygiene compliance had increased across facilities following 250 
national initiatives prior to 2009. There were no notable HCA-CDI outbreaks from 2010-251 
2014.  252 
LOS 253 
Median LOS was reduced for respiratory infections (4.8 to 4.3 days, p<0.01), cellulitis (3.2 to 254 
2.9 days, p<0.01), urinary and kidney infections (3.3 to 2.9 days, p<0.01), and septicaemia 255 
(6.8 to 6.1 days, p<0.01; Table 3). Over the same time period, median LOS for all hospital 256 
admissions also decreased from 2.1 to 1.9 days (p<0.01). 257 
In-hospital SMR 258 
SMRs decreased for respiratory infections (1.10 [95%CI 1.01-1.20] to 0.75 [0.68-0.82] 259 
observed/expected deaths), urinary and kidney infections (0.78 [0.52-1.10] to 0.63 [0.42-260 
0.91]), and septicaemia (1.25 [1.12-1.38] to 0.80 [0.72-0.89]).  Reductions in those infection-261 
related SMRs were in line with the reduction in background SMR (1.19 [1.15-1.23] to 0.90 262 
[0.87-0.93]; Table 3). A small increase was observed for cellulitis (0.55 [0.28-0.95] to 0.66 263 
[0.38-1.05]). 264 




To our knowledge, this is the first study to evaluate implementation of a multisite ASP 267 
supported by a centrally deployed CDSS. We found significant improvements in 268 
antimicrobial use, demonstrated by changes in antimicrobials targeted for increased and 269 
decreased use. There were significant reductions in antimicrobial costs and HCA-CDI rates. 270 
Safety of the intervention was supported by decreased or unchanged LOS and SMRs for key 271 
infections during the study period. The long-term impact of the intervention on 272 
antimicrobial use and cost diminished over time, which suggests that ongoing program 273 
reinforcement and targeted interventions may be required to alleviate “antimicrobial 274 
stewardship fatigue”. Changes in overall antimicrobial use prior to the main intervention 275 
probably resulted from an intensive education campaign across the hospitals, with 276 
heightened awareness of the impending change among clinicians. The importance of 277 
readiness assessments prior to implementation was recognised, along with shared 278 
interventions across the study hospitals. Those included antimicrobial stewardship ward 279 
rounds with post-prescription review and feedback, consensus guidelines, and antimicrobial 280 
restriction. 281 
Some studies have evaluated ASPs across multiple hospital sites8, 9, 31 and the utility of an 282 
individual site CDSS for improvement in antimicrobial prescribing;3, 32-34 however, the 283 
combination of these two approaches is novel. Furthermore, this collaborative ASP was 284 
applied to non-metropolitan settings with an established structure of support from a larger 285 
hospital. Pooling data across five hospitals enhanced the potential to identify effects of the 286 
ASP. Few randomised studies have been conducted to determine the effect of ASPs.8, 12 Our 287 
study used interrupted time series analysis, which is considered an alternative pragmatic 288 
 
 
approach with strong quasi-experimental design.35 Comparison with control hospitals would 289 
have strengthened the study design; however, there were none available in the health 290 
districts due to widespread implementation of the ASP. 291 
Our study demonstrates that shared knowledge and expertise can be used to effectively 292 
implement an ASP across multiple hospital sites spanning a wide geographic area. The 293 
economies of scale enjoyed by the multisite approach allowed for collective interventions to 294 
be employed with reduced workload at individual hospital sites. Multisite implementation 295 
also alleviated some of the potential disadvantages of the CDSS, such as resources required 296 
for implementation and maintenance.2 An additional benefit of extensive multisite 297 
intervention was consistency in antimicrobial prescribing guidelines, facilitating the training 298 
of medical officers rotating through the facilities within the districts’ different hospitals. A 299 
consistent, multisite approach was also anticipated to enhance prescriber confidence and 300 
facilitate the quality improvement culture necessary to effect longer term improvements in 301 
antimicrobial prescribing.36, 37 302 
ASPs are a key element of the approach to reducing HCA-CDI.38 Importantly, our 303 
intervention was associated with a reduction in HCA-CDI rates, as well as a decrease in trend 304 
that persisted over time. This occurred in the context of increasing community CDI rates.39  305 
The specialist paediatric hospital and paediatric wards from study sites were not included in 306 
this analysis. Non-comparability of standard adult metrics such as DDDs results in difficulty 307 
benchmarking antimicrobial use in children.40 HCA-CDI cannot easily be assessed in the 308 
paediatric population due to asymptomatic carriage in infants and lower rates of 309 
symptomatic CDI in children.41 Although quantitative paediatric data were not included in 310 
 
 
this study, paediatric guideline and CDSS development were important for multisite ASP 311 
implementation across the network of small rural to large metropolitan hospitals.  312 
Maintaining cost effectiveness is of concern to administrators.42 Placing drug costs as the 313 
primary measure of cost analysis does not take into account changes in acquisition costs 314 
(e.g. when drugs come off patent). In addition, the most appropriate antimicrobial is not 315 
necessarily the lowest in price. Identifying other methods of cost benefit analysis is justified, 316 
such as the impact of healthcare associated infections, and the increased cost of treating 317 
resistant organisms.43 Some cost savings were attributed to reductions in drug acquisition 318 
costs, such as for meropenem in 2011. Paradoxically, the intervention was associated with 319 
increased drug costs in some instances. Benzylpenicillin, targeted for increased use, had a 320 
daily cost at usual dosing (1.2g intravenously 6 hourly) of AUD$25, compared with 321 
ceftriaxone (targeted for decreased use; AUD$1.30 for 1g intravenously daily). In addition, 322 
the post-intervention cost increase may have been driven by high cost antifungal use where 323 
treatment of a small number of patients may result in a significant increase in drug costs. 324 
Building works at some of the sites, leading to increased prophylaxis and treatment of 325 
invasive fungal infections, may have led to this increase. However, antifungals were not a 326 
main target of the collaborative ASP as they were already highly restricted prior to the 327 
intervention. Costs of the intervention were not analysed as part of this study; there were 328 
costs associated with purchasing the CDSS, and additional pharmacy and ID resources in 329 
supporting the ASPs.  330 
There were some other limitations to this study. Antimicrobial use patterns may also have 331 
been affected by unforeseen drug shortages and changes to infection control practices. 332 
There were no systematic changes to the infection control policies across the districts during 333 
 
 
the study period, and no recognised outbreaks of CDI occurred during this time. Some 334 
measures were not included due to a lack of comparable pre- and post-intervention data 335 
across sites; these included the impact of antimicrobial stewardship ward rounds, point 336 
prevalence survey results and antimicrobial resistance patterns. Antimicrobials analysed 337 
included only those targeted for increased (e.g. benzylpenicillin) or decreased (e.g. 338 
ceftriaxone) use. Not all antimicrobial classes were reported individually, such as 339 
glycopeptides (e.g. vancomycin) and first generation cephalosporins (e.g. cephazolin, 340 
cephalexin). Although often targeted in ASPs, based on national guidelines21 there were 341 
instances where these classes were targeted for either increased or decreased use. As such, 342 
it was not clear whether the ASP would result in a change to use. Reserve antibacterial 343 
agents such as linezolid and daptomycin were already highly restricted prior to the 344 
intervention, requiring prior physician approval before use.  345 
The effect of the intervention was not uniform across the sites. Reasons for this variability 346 
may have included differences in maturity of existing antimicrobial stewardship initiatives 347 
prior to the introduction of the CDSS, disparate levels of acuity, and variable patterns of 348 
resistance. Pre-existing antimicrobial stewardship initiatives at all sites consisted of selective 349 
microbiology reporting, limited ID and microbiology phone support, and some departmental 350 
education, with one site additionally using a phone-based approval system (Figure 1). There 351 
was variation in case complexity and case mix between study hospitals, which may have 352 
justified some differences in antimicrobial use. Additionally, seasonal variation was evident 353 
in the antimicrobial use patterns. Those confounders may have been alleviated by using 354 
combined antimicrobial use data with sufficient pre- and post-intervention time points for 355 
the ITS analysis. Data on antimicrobial use, cost and HCA-CDI data could not be aligned 356 
 
 
perfectly in time with LOS and mortality data due to report limitations; however, the 357 
maximum lag (for one hospital) was only 6 weeks over a 48 month period.  Infection-related 358 
and overall LOS decreased after the intervention, which may have been due to increased 359 
use of hospital in the home services. There may have been potential confounders, such as 360 
changes to funding and hospital admission models that affected LOS and SMR during the 361 
intervention which were difficult to quantify. However, LOS and SMR were included as 362 
important balancing measures as they could potentially be negatively impacted by changed 363 
patterns of antimicrobial use. Statewide programs were also introduced by the New South 364 
Wales Clinical Excellence Commission through 2010-2014 to improve management of 365 
deteriorating patients (Between the Flags program) and recognition and management of 366 
sepsis (Sepsis Kills program).44 Those initiatives potentially contributed to the improvements 367 
in LOS and SMR in the post-intervention period.  368 
We anticipate that our findings would be generalisable to healthcare facilities with potential 369 
for utilising shared resources, such as those with existing professional or political networks. 370 
Additional studies using prospective methodological approaches in different settings would 371 
help to validate our results.  372 
Conclusion 373 
Implementation of a multisite ASP supported by a centrally deployed CDSS was associated 374 
with significant changes to targeted antimicrobial use, containment of antimicrobial 375 
expenditure and reduction in HCA-CDI, without obvious adverse effects. Ongoing targeted 376 
interventions involving education and behaviour change are required to sustain the benefits 377 
of ASPs on hospital antimicrobial use. 378 
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Figure 1: Population, clinical setting, nature and timing of interventions 502 




Star symbol *Exclusions: delayed implementation, hospital sites had delayed recruitment of 505 
specialist staff and inadequate reporting of antimicrobial benchmarking data; data not 506 
comparable, specialist children’s and women’s hospitals with non-comparable patient and 507 
case mix; small sample size, antimicrobial use and cost data not reported to the National 508 
Antimicrobial Utilisation Surveillance Program (NAUSP); CDI, LOS and mortality data not 509 
analysed due to small sample size and high proportion of sub-acute admissions 510 
 511 
 512 
  513 
 
 
  514 
 
 
Figure 2: Impact of CDSS-supported multisite ASP on monthly antimicrobial use  515 
Abbreviations: DDDs, defined daily doses; OBDs, occupied bed days  516 
Targeted for increased use: benzylpenicillin, doxycycline, aminopenicillins (amoxicillin and 517 
ampicillin); targeted for decreased use: third generation cephalosporins (ceftriaxone, 518 
cefotaxime), macrolides (azithromycin, clarithromycin, erythromycin, roxithromycin), anti-519 
pseudomonal penicillins (piperacillin/tazobactam, ticarcillin/clavulanic acid), 520 
fluoroquinolones (ciprofloxacin, moxifloxacin, norfloxacin); carbapenems (ertapenem, 521 
doripenem, imipenem/cilastatin, meropenem) total antimicrobials, all antimicrobials 522 
excluding antifungals and antivirals; vertical line is introduction of a CDSS-supported ASP, 523 
including antimicrobial restriction and education.  524 




  527 
Figure 3: Impact of CDSS-supported multisite ASP on monthly healthcare associated 528 
Clostridium difficile infection rates 529 
Abbreviations: HCA-CDI, healthcare associated Clostridium difficile infection 530 
Two years of monthly HCA-CDI rates pre- and post-intervention; vertical line is introduction 531 
of a CDSS-supported ASP. 532 
  533 
 
 
Table 1: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use 
 Pre-intervention Post-intervention 
Antimicrobial Initial 
level 
LCI UCI Initial 
trend 








LCI UCI p 
value 
Combined targeted 
for increased use 
182
a
 170 195 1.7
a
 0.7 2.8 <0.01 71
a
 43 98 <0.01 -3.5
a
 -5.3 -1.7 <0.01 
Combined targeted 
for decreased use 





 1033 1184 -3.4
a
 -8.9 2.1 0.22 -29
a
 -129 71 0.57 3.55
a
 -2.6 9.7 0.25 
Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days for five hospitals, as reported to NAUSP; trends: 
positive value represents increase, negative value represents decrease; 95% confidence intervals expressed as LCI (lower confidence interval) 
and UCI (upper confidence interval); aadjusted for first order autocorrelation; targeted for increased use: benzylpenicillin, doxycycline, 
aminopenicillins (amoxycillin, ampicillin); targeted for decreased use: third generation cephalosporins (ceftazidime, cefotaxime, ceftriaxone); 
macrolides (azithromycin, clarithromycin, erythromycin, roxithromycin); anti-pseudomonal penicillins (piperacillin/tazobactam, 
ticarcillin/clavulanic acid); fluoroquinolones (ciprofloxacin, moxifloxacin, norfloxacin); carbapenems (meropenem, ertapenem, doripenem, 




Table 2: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare associated Clostridium difficile infection 
 Pre-intervention Post-intervention  
Variable Initial 
level 
LCI UCI Initial 
trend 
















 417101 509649 -3196
a
 -5759 -633 0.02 -64551
a
 -106056 -23044 <0.01 7273
a
 3899 10649 <0.01 
Costs per 
OBD ($AU) 





92575 67721 117429 2021 376 3666 0.02 -50270 -86637 -13903 <0.01 1117 -1504 3738 0.40 
HCA-CDI per 
10,000 OBDs 
2.8 1.7 3.9 0.14 0.06 0.22 <0.01 -1.2 -2.8 0.4 0.15 -0.2 -0.3 0.1 <0.01 
Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection. 
aadjusted for first order autocorrelation; trends: positive value represents increase, negative value represents decrease; bantibacterial, 
antifungal, antiviral chigh cost antifungals: liposomal amphotericin, anidulafungin, caspofungin, posaconazole, voriconazole; individual hospital 




Table 3: Length of stay and standardised mortality ratio by clinical infection group 
 Length of stay  Standardised mortality ratio 
 July 10 – June 12 July 12 – June 14  July 10 – June 12 July 12 – June 14 
Outcome 
measure 
Episodes Median LOS 
(IQR), days 
Episodes Median LOS  
(IQR), days 
p value Standardised 













5,489 4.8 (2.8-7.8) 5640 4.3 (2.5-7.1) <0.01 1.10 (1.01-1.20) 534/485 0.75 (0.68-0.82) 436/584 
Cellulitis 3,696 3.2 (1.6-5.8) 3757 2.9 (1.2-5.0) <0.01 0.55 (0.28-0.95) 12/22 0.66 (0.38-1.05) 17/26 
Urinary and 
kidney infections  
4,323 3.3 (1.2-5.2) 4364 2.9 (1.0-5.2) <0.01 0.78 (0.52-1.10) 30/39 0.63 (0.42-0.91) 29/46 
Septicaemia 1,610 6.8 (4.0-11.7) 2441 6.1 (3.5-10.9) <0.01 1.25 (1.12-1.38) 350/281 0.80 (0.72-0.89) 359/450 
Overall 224,021 2.1 (0.6-5.6) 242,383 1.9 (0.5-5.0) <0.01 1.19 (1.15-1.23) 3795/3193 0.90 (0.87-0.93) 3647/4063 
Abbreviations: LOS, length of stay; IQR, interquartile range; CI, confidence interval  
Respiratory infections/inflammations, code E62; cellulitis, code J64; urinary and kidney infections, code, L63; septicaemia, code T60; overall 
LOS excludes haemodialysis day admissions. Codes for LOS used Australian refined diagnosis related group definitions; codes for SMR used 













Top five DRGs by volume 
Prince of Wales 32,699 49,513 1.51 Chest pain; cellulitis; other digestive system diagnosis; respiratory infection/ 
inflammation; injuries 
Shellharbour 8,213 11,246 1.37 Respiratory infection/ inflammation; schizophrenia disorders; chronic obstructive 
airway disease; hernia procedures; personality disorder and acute reactions 
Shoalhaven 10,970 12,678 1.16 Uncomplicated neonatal admission; vaginal delivery; respiratory infection/ 
inflammation; chronic obstructive airway disease; caesarean delivery 
St George 39,234 57,138 1.46 Uncomplicated neonatal admission; vaginal delivery; chest pain; respiratory 
infection/ inflammation; oesophagitis and gastroenteritis 
Wollongong 36,951 50,813 1.38 Uncomplicated neonatal admission; vaginal delivery; respiratory infection/ 
inflammation; cellulitis; caesarean delivery 
 
Australian financial year, 1 July 2013 to 30 June 2014; total acute episodes excludes haemodialysis, due to a large number of episodes without 
significant antimicrobial use; NWAU(16), National weighted activity unit (2015/16), a measure of comparing and valuing each public hospital 
service, to determine the overall complexity and relative resource payment for services funded on an activity basis. DRGs, Australian-refined 
diagnosis related group.  
 
 
Supplementary Table 2: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, Prince of Wales Hospital  
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 















 11 28 0.5 -0.1 1.2 0.1 4.9 -8.6 18.4 0.5 -0.3 -1.2 0.6 0.5 
Doxycycline 10
a
 5 15 2 1.5 2.5 <0.01 4.4 -6.8 15.6 0.4 -1.8 -2.6 -0.9 <0.01 
Aminopenicillins 146
a
 129 163 -0.8 -1.8 0.3 0.15 3.0 9.3 47.5 <0.01 0.4 -1.0 1.7 0.6 
Combined 175
a








 gen cephalosporins 75
a
 68 83 -0.6 -1.0 -0.3 <0.01 1.7 -4.7 8.2 0.6 0.8 0.2 1.5 0.01 
Macrolides 95
a





 23 33 0.7 0.4 1.0 <0.01 -4.9 -13 3.3 0.24 -0.67 -1.1 -0.2 <0.01 
Fluoroquinolones 72 62 81 -1.8 -1.4 -0.2 0.01 -0.2 -12 12 0.98 0.1 -1 1.1 0.87 
Carbapenems 25 17 34 0.4 -0.2 1.0 0.2 3.4 -7.4 14 0.5 -0.5 -1.3 0.3 0.25 
Combined 296 270 322 -0.9 -2.7 0.8 0.3 -13 -47 21 0.4 0.1 -2.4 2.5 0.9 
Total antimicrobial use 1109
a
 1078 1140 0.8 -3.2 1.6 0.5 69 20 119 <0.01 3.6 -0.8 8.1 0.1 
Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days, as reported to NAUSP; 95% confidence intervals 
expressed as LCI (lower confidence interval) and UCI (upper confidence interval); trends: positive value represents increase, negative value 
represents decrease.  
 
 
aadjusted for first order autocorrelation; aminopenicillins, amoxycillin, ampicillin; third generation cephalosporins, ceftriaxone and cefotaxime; 
macrolides, azithromycin, clarithromycin, roxithromycin, erythromycin; anti-pseudomonal penicillins, piperacillin-tazobactam and ticarcillin-
clavulanic acid; fluoroquinolones, ciprofloxacin, moxifloxacin and norfloxacin; carbapenems, ertapenem, doripenem, imipenem/cilastatin, 
meropenem. 
Supplementary Table 3: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, Shellharbour Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 













Benzylpenicillin 13 -1.1 26 0.17 -0.8 1.2 0.7 35 17 53 <0.01 -1.4 -2.7 -0.1 0.03 
Doxycycline 22
a
 8 35 5.2 3.9 6.5 <0.01 74 33 115 <0.01 -7 -10 -4 <0.01 
Aminopenicillins 98
a
 80 117 -0.2 -1.6 1.2 0.75 53 25 81 <0.01 -1.3 -2.9 0.3 0.1 
Combined 132
a








 gen cephalosporins 94 78 110 -1.2 -2.9 0.6 0.19 -29 -59 2 0.06 2.1 0.3 3.9 0.02 
Macrolides 295 259 331 -6.1 -8.7 -3.4 <0.01 -65 -127 -3.4 0.04 5.7 2.9 8.4 <0.01 
Anti-pseudomonal 
penicillins 
17 13 21 0.03 -0.3 0.3 0.88 -8 -15 -1 0.02 0.25 -0.2 0.7 0.28 
Fluoroquinolones 55 35 75 -0.001 -1.6 1.6 1 -30 -58 -1 0.04 0.7 -1.3 2.6 0.5 
Carbapenems 5 2 7 -0.05 -0.2 0.1 0.57 -1.5 -5 2 0.41 0.2 -0.1 0.5 0.18 
 
 
Combined 466 400 530 -7.3 -13 -1.2 0.02 -133 -245 -22 0.02 8.9 1.9 16 0.01 
Total antimicrobial use 1295
a










Supplementary Table 4: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, Shoalhaven Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 













Benzylpenicillin 36 22 49 0.03 -1.1 1.2 1 9 -13 31 0.8 -0.2 -1.5 1.1 0.7 
Doxycycline 108
a
 71 143 0.4 -1.7 2.6 0.7 54 26 81 <0.01 -1.1 -3.5 1.3 0.4 
Aminopenicillins 202
a
 190 214 -2.4 -3.3 -1.5 <0.01 19 -11 49 0.2 2.2 0.2 4.1 0.03 
Combined 344
a








 gen cephalosporins 54 42 67 0.3 -0.5 1.0 0.5 -16 -27 -6 <0.01 -0.5 -1.4 0.4 0.24 
Macrolides 170 153 187 -3.2 -4.4 -1.9 <0.01 -40 -84 3 0.07 5.1 -0.3 11 0.06 
Anti-pseudomonal 
penicillins 
21 16 26 -0.01 -0.3 0.3 0.97 -5 -12 1.7 0.14 0.63 -0.02 1.3 0.06 
Fluoroquinolones 66 57 75 -1 -1.7 -0.3 <0.01 -13 -30 3.4 0.12 0.85 -0.2 1.9 0.12 
Carbapenems 9
a
 6 11 -0.2 -0.3 -0.01 0.04 -2 -6.5 2.5 0.37 0.4 0.1 0.8 0.02 
Combined 320 293 346 -4.1 -5.8 -2.3 <0.01 -77 -128 -27 <0.01 6.5 0.9 12 0.02 
Total antimicrobial use 1508
a











Supplementary Table 5: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, St George Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 















 14 27 0.7 0.2 1.2 <0.01 -16 -24 -7 <0.01 -0.1 -0.7 0.4 0.6 
Doxycycline 1.4
a
 -2.9 5.6 1.1 0.84 1.43 <0.01 -0.1 -8.5 8.3 0.98 -1.0 -1.6 -0.5 <0.01 
Aminopenicillins 75
a
 69 81 2.0 1.28 2.69 <0.01 8.1 -6.8 23.0 0.3 -3.8 -4.7 3.0 <0.01 
Combined 96
a








 gen cephalosporins 44 37 50 0.5 0 1.06 0.051 -4.0 -14 6.1 0.43 -0.9 -1.5 -0.3 <0.01 





 15 20 0.8 0.6 1.0 <0.01 -7 -12 -2 <0.01 -0.08 -0.4 0.2 0.6 
Fluoroquinolones 29
a
 24 34 0.2 -0.1 0.5 0.13 -5 -9 -1 0.02 -0.1 -0.5 0.2 0.43 
Carbapenems 13
a
 10 15 0.1 -0.02 0.3 0.09 3.2 -2.4 8.8 0.25 -0.1 -0.4 0.2 0.5 
Combined 183 165 202 2.5 0.8 4.3 <0.01 -19 -54 15 0.27 -3.3 -5.4 -1.2 <0.01 











Supplementary Table 6: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, Wollongong Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 













Benzylpenicillin 20 15 26 -0.3 -0.7 0.06 0.1 18 11 25 <0.01 -0.05 -0.6 0.5 0.8 
Doxycycline 30
a
 19 40 1.2 0.1 2.3 0.03 35 8 61 0.01 -2.5 -4 -1 <0.01 
Aminopenicillins 114
a
 104 124 -1.2 -2.1 -0.3 0.01 27 11 44 <0.01 0.8 -0.3 1.9 0.15 
Combined 164
a








 gen cephalosporins 51 42 61 -0.3 -0.9 0.4 0.4 -8 -17 1 0.08 0.56 -0.2 1.3 0.12 





 41 58 -0.3 -0.9 0.2 0.24 -7 -15 1.5 0.1 0.7 0.05 1.3 0.04 
Fluoroquinolones 73 63 83 -1 -1.8 -0.3 <0.01 -16 -30 -4 0.01 1.3 0.5 2.1 <0.01 
Carbapenems 19
a
 15 23 0.01 -0.2 0.2 0.87 -3 -10 3 0.3 0.6 0.2 1.0 <0.01 
Combined 316 283 349 -3.6 -6.0 -1.2 <0.01 -48 -88 -7 <0.01 4.6 1.8 7.4 <0.01 
Total antimicrobial use 1081
a





Supplementary Table 7: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium 
difficile infection rates, Prince of Wales Hospital 
 Pre-intervention Post-intervention 
Variable Initial 
level 
LCI UCI Initial 
trend 








LCI UCI p 
value 
Total costs ($AU) 174984
a
 135818 214149 -2006 -4201 188 0.07 -7440 -37329 22449 0.62 2853 297 5410 0.03 
Total costs per OBD 
($AU) 
12 10 14 -0.15 -0.3 -0.003 0.045 -1.5 -3.5 0.5 0.15 0.55 0.35 0.75 <0.01 
Antifungal
b
 costs ($AU) 56110
a
 -705 2803 87 -1218 1391 0.9 -13288 -34951 8375 0.22 1049 -705 2803 0.23 
HCA CDI per  
10000 OBDs (n) 
5.5 3.6 7.5 0.08 -0.05 0.2 0.2 0.4 -3.2 4.0 0.8 -0.24 -0.5 -0.01 0.04 
Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection. 





Supplementary Table 8: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium 
difficile infection rates, Shellharbour Hospital 
 Pre-intervention Post-intervention 
Variable Initial 
level 
LCI UCI Initial 
trend 




LCI UCI p value Change 
in trend 
LCI UCI p 
value 
Total costs ($AU) 12274 10351 14196 -37 -196 123 0.65 -2708 -6074 657 0.11 36 -175 247 0.73 




 3.5 5.0 -0.02 -0.08 0.05 0.6 -0.85 -2 0.3 0.15 0.05 -0.02 0.11 0.16 
Antifungal
b
 costs ($AU) -88 -129 31 51 -29 130 0.2 -1177 -2893 540 0.17 -49 129 31 0.22 
HCA CDI per  
10000 OBDs (n) 










Supplementary Table 9: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium 
difficile infection rates, Shoalhaven Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 








LCI UCI p 
value 
Total costs ($AU) 28629 21020 36238 -624 -1037 -210 <0.01 89 -4122 4299 0.97 639 201 1077 <0.01 
Total costs per OBD 
($AU) 
8.5 6.2 109 -0.2 -0.3 -0.1 <0.01 0.14 -1.1 1.4 0.83 0.24 0.1 0.4 <0.01 
Antifungal
b
 costs ($AU) 4409
a
 23 386 -213 -368 -58 <0.01 2225 404 4046 0.02 204 22.5 386 0.03 
HCA CDI per  
10000 OBDs (n) 





Supplementary Table 10: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium 
difficile infection rates, St George Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 








LCI UCI p 
value 
Total costs ($AU) 104693
a
 84724 124662 1688 206 3170 0.03 -61611 -85528 -37694 <0.01 828 -873 2529 0.33 




 5.95 8.33 0.19 0.02 0.22 0.02 -4.7 -6.5 -2.9 <0.01 0.1 -0.01 0.23 0.06 
Antifungal
b
 costs ($AU) 11112 -6465 28689 1998 390 3606 0.02 -46943 -74954 -18932 <0.01 -300 -2011 1411 0.73 
HCA CDI per  
10000 OBDs (n) 














Supplementary Table 11: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium 
difficile infection rates, Wollongong Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 








LCI UCI p  
value 
Total costs ($AU) 142796 122788 162803 -2218 -3396 -1040 <0.01 7120 -19333 33573 0.6 2917 1138 4667 <0.01 
Total costs per OBD 
($AU) 
12.3 10.6 14.1 -0.2 -0.3 -0.1 <0.01 0.5 -1.6 2.6 0.6 0.27 0.12 0.41 <0.01 
Antifungal
b
 costs ($AU) 21032 -1051 1476 98 -713 908 0.8 8912 -6418 24242 0.25 212 -1051 1476 0.74 
HCA CDI per  
10000 OBDs (n) 
1.6 0.5 2.6 0.15 0.06 0.24 <0.01 -1.9 -4.1 0.33 0.09 -0.08 -0.21 0.06 0.25 
 
  
 
 
 
  
 
 
 
